全国静脉输液短缺期间限制围术期输液对手术结局的影响分析
本研究基于本地NSQIP与MBSAQIP数据,回顾IVFR期间妇科、整形、泌尿及普外科手术,按术式和9项NSQIP合并症风险因素1:1倾向评分匹配历史对照。2,028例匹配患者中,IVFR期与前期在住院时长、输血、死亡、再入院、再手术及30天并发症上均无显著差异,且机构数据显示输液用量与成本下降。结论认为围术期限制静脉输液不损害术后结局。
要点
- 妇科、泌尿、整形及普外科围术期限制静脉输液未增加30天并发症或死亡风险。
- 匹配后两组住院时长、输血、再入院及再手术率均无显著差异。
- 限制输液期间机构输液用量减少且成本降低,支持修订围术期输液方案。
核心结论
- 妇科、泌尿、整形及普外科手术围术期限制静脉输液不负面影响术后结局。
- 应修订围术期输液方案以减少医院成本与浪费而不损害患者照护。
研究设计与样本
- 回顾性队列研究,使用本地NSQIP与MBSAQIP数据集。
- IVFR期手术病例按术式及9项NSQIP合并症风险因素与IVFR前历史对照行1:1随机倾向评分匹配。
- 共2,028例匹配患者,每组1,014例;平均年龄55.4岁,女性76.7%,白人91.8%,黑人6.8%。
主要发现
- IVFR期与前期在住院时长、输血、院内死亡、30天死亡、30天再入院及30天非计划再手术上均无显著差异。
- 30天并发症(含手术部位感染、裂开、肾功能不全或衰竭、肺炎、呼吸衰竭、静脉血栓栓塞、心脏骤停或梗死、卒中)无显著差异。
- 机构数据确认IVFR期间静脉输液用量减少且成本降低。
临床怎么用
- 在妇科、泌尿、整形及普外科围术期可安全实施静脉输液限制方案以节约资源与成本。
- 可参考本机构IVFR方案修订围术期输液管理流程,但需结合本地实际。
局限性
- 为单中心回顾性研究,结果外推需谨慎。
- 仅纳入妇科、泌尿、整形及普外科手术,未覆盖其他外科专业。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hurricane Helene severely damaged the Baxter Pharmaceutical Plant in North Cove, North Carolina, in the fall of 2024, resulting in a national shortage of IV fluids. Our institution implemented an IV fluid restriction (IVFR) protocol to conserve supply across many domains of the hospital, including the perioperative space. STUDY DESIGN: Gynecologic, plastic, urologic, and general surgery procedures performed during the IVFR period were reviewed in our local NSQIP and MBSAQIP datasets. These cases were matched to historical controls from the pre-IVFR period using random 1:1 propensity score matching of the procedure and the 9 top NSQIP comorbid risk factors for overall morbidity. Perioperative and 30-day outcomes were then compared between the separate cohorts. RESULTS: There were 2,028 matched patients with 1,014 in each group. Patients had a mean age of 55.4 years, were 76.7% women, 91.8% White, and 6.8% Black. Procedures and comorbidities were well matched. There was no significant difference between the pre-IVFR and IVFR periods in length of stay, blood transfusion, hospital mortality, 30-day mortality, 30-day readmission, 30-day unplanned return to the operating room, and 30-day morbidity (including surgical site infection, dehiscence, renal insufficiency or failure, pneumonia, respiratory failure, venous thromboembolism, cardiac arrest or infarct, and stroke). Institutional data confirmed a decrease in IV fluid use and demonstrated lowered costs during the IVFR period. CONCLUSIONS: Perioperative IVFR for gynecologic, urologic, plastic, and general surgery operations does not negatively impact postoperative outcomes. Efforts should be made to revise perioperative fluid administration protocols to reduce hospital costs and waste without compromising patient care.
引用
- Hubbuch JC, Davenport DL, Nickols A, et al. Analysis of Surgical Outcomes During a Period of Intravenous Fluid Restriction as a Result of a National Shortage. J Am Coll Surg. 2026. PMID: 41532637. doi:10.1097/XCS.0000000000001762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。